EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Brain Penetrant Calcium Channel Blockers Were Not Associated With Reduced Alcohol Consumption: Converging Results From Two Large Independent Cohort Studies Using Electronic Health Records

Christopher T Rentsch iD, Vanessa A Palzes iD, Mingjian Shi iD, Michael R Setzer, Samantha G Malone, Andrea H Kline-Simon iD, Emma L Winterlind iD, Lorenzo Leggio iD, Vincent Lo Re iD, David A Fiellin iD, John Tazare iD, Mehdi Farokhnia iD und 3 weitere

Pharmacoepidemiology and Drug Safety · 2026

DOI: 10.1002/pds.70487 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2026. Verfasst von Christopher T Rentsch und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Calcium Channel Blockers, Alcohol Drinking, Brain, Alcoholism. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Department of Defense, NIAAA NIH HHS, U.S. Department of Veterans Affairs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Alcohol use disorder (AUD) remains a major public health problem, with few effective treatments. L‐type calcium channel blockers (LTCCBs) have genetic and preclinical support as potential treatments for AUD.

Methods

We evaluated whether brain penetrant (BP)‐LTCCBs are associated with reduced alcohol consumption in two preregistered observational cohort studies using electronic health records from the US Department of Veterans Affairs (VA) and Kaiser Permanente Northern California (KPNC). New users of BP‐LTCCBs (nifedipine or felodipine) were compared with new users of a non‐BP‐LTCCB (amlodipine) and with unexposed patients from the same clinics, requiring a 180‐day washout and ≥ 60 days' supply. Propensity score matching was performed across all exposure contrasts. The primary outcome was change in drinks per week from pre‐index to end of follow‐up using difference‐in‐differences (DiD) models, with prespecified subgroup analyses by AUD diagnosis, drinking level, and sex.

Results

Across both health systems, BP‐LTCCB initiation was not associated with greater reductions in drinks per week than either comparator, with broadly consistent findings across all subgroups; though some subgroups were small and imprecise. In the VA, the DiD comparing BP‐LTCCB with non‐BP‐LTCCB was 0.14 drinks/week (95% CI −0.06, 0.34), and versus unexposed was 0.00 (95% CI −0.18, 0.19). Similar results were observed in KPNC (BP‐LTCCB vs. non‐BP‐LTCCB: 0.31, 95% CI −0.48, 1.11; BP‐LTCCB vs. unexposed: 0.16, 95% CI −0.67, 0.99).

Conclusions

In two large, preregistered EHR‐based cohorts, we found no evidence that BP‐LTCCBs were associated with reduced drinking relative to comparators. Despite compelling genetic and preclinical evidence, these findings do not support repurposing BP‐LTCCBs for AUD and instead prioritize alternative pharmacologic targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Calcium Channel BlockersAlcohol DrinkingBrainAlcoholismHumansElectronic Health RecordsMaleFemaleCohort StudiesMiddle AgedUnited StatesUnited States Department of Veterans AffairsAgedCaliforniaFelodipineAdult

Stichwörter der Autor:innen

alcohol use disordercalcium channel blockersdifference‐in‐differences analysisdrug repurposingelectronic health recordsreal‐world evidence

Substanzen

Calcium Channel BlockersFelodipine

Autor:innen und Institutionen

  • Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
  • Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.
  • Center for Addiction and Mental Health Research, Division of Research, Kaiser Permanente Northern California, Oakland, California, USA.
  • Department of Medical and Clinical Psychology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Henry M. Jackson Foundation for the Advancement of Military Medicine Inc., Bethesda, Maryland, USA.
  • Department of Psychology, University of Wyoming, Laramie, Wyoming, USA.

ORCID-Profile: Christopher T Rentsch, Vanessa A Palzes, Mingjian Shi, Andrea H Kline-Simon, Emma L Winterlind, Lorenzo Leggio, Vincent Lo Re, David A Fiellin, John Tazare, Mehdi Farokhnia, Stacy Sterling, Henry R Kranzler, Joshua C Gray

Förderung

  • U.S. Department of Defense
  • NIAAA NIH HHS
  • U.S. Department of Veterans Affairs
  • BLRD VA
  • National Institute on Alcohol Abuse and Alcoholism

Zitieren

APA

Rentsch, C. T., Palzes, V. A., Shi, M., Setzer, M. R., Malone, S. G., Kline-Simon, A. H., Winterlind, E. L., Leggio, L., Lo Re, V., Fiellin, D. A., Tazare, J., Farokhnia, M., Sterling, S., Kranzler, H. R., & Gray, J. C. (2026). Brain Penetrant Calcium Channel Blockers Were Not Associated With Reduced Alcohol Consumption: Converging Results From Two Large Independent Cohort Studies Using Electronic Health Records. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70487

Vancouver

Rentsch CT, Palzes VA, Shi M, Setzer MR, Malone SG, Kline-Simon AH, et al. Brain Penetrant Calcium Channel Blockers Were Not Associated With Reduced Alcohol Consumption: Converging Results From Two Large Independent Cohort Studies Using Electronic Health Records. Pharmacoepidemiology and Drug Safety. 2026. doi:10.1002/pds.70487

BibTeX
@article{Rentsch2026,
  author = {Rentsch, Christopher T and Palzes, Vanessa A and Shi, Mingjian and Setzer, Michael R and Malone, Samantha G and Kline-Simon, Andrea H and Winterlind, Emma L and Leggio, Lorenzo and Lo Re, Vincent and Fiellin, David A and Tazare, John and Farokhnia, Mehdi and Sterling, Stacy and Kranzler, Henry R and Gray, Joshua C},
  title = {Brain Penetrant Calcium Channel Blockers Were Not Associated With Reduced Alcohol Consumption: Converging Results From Two Large Independent Cohort Studies Using Electronic Health Records},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2026},
  doi = {10.1002/pds.70487}
}
Kostenlos starten →